Genmab A/S (NASDAQ:GMAB) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $50.00 price target on the stock.

GMAB has been the topic of a number of other reports. Morgan Stanley restated an underweight rating on shares of Genmab A/S in a report on Tuesday, March 26th. Truist Financial upped their price target on Genmab A/S from $50.00 to $53.00 and gave the stock a buy rating in a research report on Tuesday, June 4th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average price target of $49.50.

Genmab A/S Stock Performance

Shares of GMAB opened at $25.13 on Thursday. The stock has a 50 day simple moving average of $27.96 and a 200 day simple moving average of $29.09. Genmab A/S has a 52-week low of $24.94 and a 52-week high of $42.72. The firm has a market capitalization of $16.62 billion, a PE ratio of 20.94, a P/E/G ratio of 0.91 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The company had revenue of $603.30 million during the quarter, compared to analysts’ expectations of $594.23 million. Equities research analysts predict that Genmab A/S will post 1.11 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

A number of large investors have recently added to or reduced their stakes in GMAB. Park Place Capital Corp lifted its stake in Genmab A/S by 12.3% in the 4th quarter. Park Place Capital Corp now owns 4,891 shares of the company’s stock valued at $156,000 after purchasing an additional 535 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after acquiring an additional 544 shares during the last quarter. Grandfield & Dodd LLC raised its stake in Genmab A/S by 2.3% in the 4th quarter. Grandfield & Dodd LLC now owns 25,558 shares of the company’s stock valued at $814,000 after acquiring an additional 565 shares during the period. Envestnet Portfolio Solutions Inc. raised its stake in Genmab A/S by 2.3% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company’s stock valued at $830,000 after acquiring an additional 633 shares during the period. Finally, Pinnacle Bancorp Inc. lifted its holdings in Genmab A/S by 315.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock valued at $27,000 after purchasing an additional 638 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.